Immune Checkpoint Inhibitors: all 7,817 studies that test it

Page 47 of 79. Open to participants first (2,632), then studies with results posted, then the rest; newest registration first within each.

• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerActive, not recruitingNCT06112379Phase 3
• Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)Active, not recruitingNCT06109779Phase 3
• Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal CancerActive, not recruitingNCT06109467Phase 2
• A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)Active, not recruitingNCT06109272Phase 2/3
• Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical TrailCompletedNCT06108596Phase 2
• Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast CancerWithdrawnNCT06105008Phase 2
• KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 BlockadeActive, not recruitingNCT06099821Phase 2
• MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaActive, not recruitingNCT06097728Phase 3
• A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 CirrhosisActive, not recruitingNCT06096779Phase 2
• NEO-adjuvant Chemo-immunotherapy in Pancreatic CancerActive, not recruitingNCT06094140Phase 2
• Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT06091943Phase 1
• Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A LossWithdrawnNCT06090318Phase 1/2
• Ketohexokinase Inhibition in Hereditary Fructose IntoleranceCompletedNCT06089265Phase 2
• Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid StructuresWithdrawnNCT06084689Phase 2
• Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT06083454Phase 1
• Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCCActive, not recruitingNCT06081673Phase 2
• The Seven Trial: Exploiting the Unfolded Protein ResponseTerminatedNCT06076837Phase 1
• Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid TumorsCompletedNCT06076135Phase 2
• Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC ImmunotherapyActive, not recruitingNCT06074029Phase 1/2
• "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast CancerTerminatedNCT06067061Phase 1/2
• A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202Active, not recruitingNCT06062420Phase 2
• Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCCStatus unknownNCT06059885Phase 2
• Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell CarcinomaActive, not recruitingNCT06056895Phase 2
• Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT06055816Phase 2
• Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung CancerActive, not recruitingNCT06055465Phase 2
• A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic MelanomaActive, not recruitingNCT06054555Phase 3
• Study of ALE.C04 in Patients With Head and Neck CancerTerminatedNCT06054477Phase 1/2
• A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)WithdrawnNCT06050954Phase 2
• Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before SurgerySuspendedNCT06050252Phase 2
• Atezolizumab in Large Cell Neuroendocrine CarcinomaCompletedNCT06049966Phase 1
• Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)Active, not recruitingNCT06048133Phase 2
• GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial CancerWithdrawnNCT06046274Phase 2
• A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)Active, not recruitingNCT06041802Phase 2
• A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)Active, not recruitingNCT06041269Phase 2
• A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TAREActive, not recruitingNCT06040099Phase 2
• Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)CompletedNCT06036836Phase 2
• A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382TerminatedNCT06032546Phase 2
• Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast CancerActive, not recruitingNCT06027268Phase 2
• Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell CarcinomaStatus unknownNCT06023875Phase 2
• Hyperthermia Combined With Immune Checkpoint Inhibitor Therapy for Advanced Gastrointestinal TumoursCompletedNCT06022692Phase 1/2
• The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant TumorActive, not recruitingNCT06022250Phase 1
• Clinical Evaluation of the AP203 Plant Extract Mixture in Adult Patients With Increased Incidence of Viral and/or Bacterial Upper Respiratory Tract InfectionsCompletedNCT06020001Not applicable
• Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic CholangiocarcinomaWithdrawnNCT06017297Phase 2
• A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Phase 2
• Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)Active, not recruitingNCT06009861Phase 2
• A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRASActive, not recruitingNCT06008093Phase 2
• A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular CarcinomaWithdrawnNCT06006286Phase 1/2
• Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) NegativeActive, not recruitingNCT06001151Phase 2
• Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal CancerActive, not recruitingNCT05999812Phase 2
• Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced MelanomaActive, not recruitingNCT05986331Phase 3
• A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic CancerActive, not recruitingNCT05984602Phase 1
• A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.Active, not recruitingNCT05984277Phase 3
• TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell CarcinomaTerminatedNCT05980598Phase 2
• A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).TerminatedNCT05975645Phase 1
• Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and ChemoradiationActive, not recruitingNCT05975307Phase 2
• Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of GlioblastomaWithdrawnNCT05973903Phase 1/2
• A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDACActive, not recruitingNCT05968326Phase 2
• The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon CancerActive, not recruitingNCT05961709Phase 2
• A Relative Bioavailability Study of Peresolimab (LY3462817) Formulations in Healthy ParticipantsCompletedNCT05959109Phase 1
• A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7SuspendedNCT05958199Phase 1
• Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After TreatmentActive, not recruitingNCT05957510Phase 2
• A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05949606Phase 1/2
• Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX TrialActive, not recruitingNCT05947500Phase 2
• BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC ParticipantsActive, not recruitingNCT05943106Phase 3
• Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II TrialStatus unknownNCT05942573Phase 2
• A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid TumorsStatus unknownNCT05942378Phase 1
• A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyActive, not recruitingNCT05941897Phase 2
• Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJCompletedNCT05941481Phase 2
• A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue SarcomaSuspendedNCT05941325Phase 2
• OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung CancerWithdrawnNCT05935774Phase 2
• AK104 for Recurrent or Metastatic Vulvar CancerTerminatedNCT05932212Phase 2
• Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before SurgerySuspendedNCT05929664Phase 2
• Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical TrialSuspendedNCT05928806Phase 2
• Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy EfficacyActive, not recruitingNCT05927142Phase 1/2
• A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced MelanomaTerminatedNCT05926960Phase 2
• Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)Active, not recruitingNCT05925530Phase 2
• A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)CompletedNCT05924880Phase 3
• PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin LymphomaActive, not recruitingNCT05922904Phase 2
• Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerActive, not recruitingNCT05920798Phase 1/2
• Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal JunctionStatus unknownNCT05918419Phase 2
• A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBCActive, not recruitingNCT05918133Phase 1/2
• A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPMCompletedNCT05918107Phase 2
• Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic CholangiocarcinomaStatus unknownNCT05913661Phase 2
• A Study of IO102/IO103, Nivolumab, and Relatlimab in People With MelanomaActive, not recruitingNCT05912244Phase 2
• Abequolixron (RGX-104) and Durvalumab in Lung CancerTerminatedNCT05911308Phase 1
• Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Active, not recruitingNCT05911295Phase 3
• Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid TumorsTerminatedNCT05909995Phase 1
• A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05908734Phase 1/2
• A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected MelanomaCompletedNCT05907122Phase 3
• A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)Active, not recruitingNCT05904886Phase 3
• AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung CancerActive, not recruitingNCT05904379Phase 1/2
• Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)WithdrawnNCT05900648Phase 2
• Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsActive, not recruitingNCT05899608Phase 3
• A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension StudyActive, not recruitingNCT05899049Phase 3
• Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal CancerWithdrawnNCT05898828Phase 1/2
• TEIPP Immunotherapy in Patients With NSCLCCompletedNCT05898763Phase 1/2
• Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLCActive, not recruitingNCT05894889Phase 2
• Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial CancersWithdrawnNCT05894447Phase 1
• A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell CarcinomaTerminatedNCT05888844Phase 2
• Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLCActive, not recruitingNCT05888402Phase 2

← Immune Checkpoint Inhibitors overview